Dr Reddy Stock

In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.

Bullish signs on charts: Hitesh Tailor of Choice Broking explains that BEL has witnessed a decisive symmetrical triangle breakout, while Dr Reddy's and Triveni Engineering saw 'Golden Crossovers'.

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.

Dr Reddy's Laboratories shares reached their all time high at Rs 7,101 per share, surging 1.95 per cent at intraday levels on Wednesday

Indian drugmaker, Dr Reddy's Laboratories is all set to deliver its financial performance for the first quarter of financial year 2024-25 (Q1FY25) on Saturday, July 27, 2024

In India, DRL has an OTC portfolio in the hydration, cough-cold-allergy, and skin care categories

With this, Dr Reddy's has become the third listed pharmaceutical company to achieve the Rs 1-trillion m-cap feat

CLOSING BELL: In the broader markets, the BSE SmallCap index outperformed the frontline indices with 0.68 per cent rise

Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.

Sales in the US, its biggest market, accounting for 37 per cent of revenues, were up 8 per cent year-on-year (YoY) and 12 per cent sequentially, led by five new launches

Weekly Technical Recommendations by Religare Broking Ltd.

The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year

Earnings were driven by one-off gains

Analysts at Nomura believe there is a strong probability that the company will get approval in the near term for Suboxone & expect initially lower competitive intensity